US Pharma Q3 Earnings Wave: Syndax, BioMarin, Vertex, Jazz Beat Revenue Estimates as Drug Launches Accelerate

The Quick Take

• Six US pharmaceutical companies reported Q3 2026 earnings with revenue beats across the board: Syndax posted $83.3M revenue (+82% YoY), BioMarin delivered $1,025M topping consensus, and Vertex exceeded estimates driven by its dominant cystic fibrosis franchise
• Jazz Pharmaceuticals reported $1.24 billion in Q3 revenue while CRISPR Therapeutics delivered $12.7M in revenue—beating the $10.49M estimate—despite GAAP losses reflecting ongoing gene therapy development costs
• The broad earnings beat across different pharma sub-sectors, from large-cap rare disease to early-stage gene therapy, signals a healthy Q3 reporting cycle with new drug launches driving revenue diversification away from legacy franchises

Six pharmaceutical companies reported Q3 2026 earnings across a broad sweep of the sector, with revenue beats at every size tier from early-stage CRISPR Therapeutics to large-cap BioMarin and Vertex Pharmaceuticals. Syndax Pharmaceuticals led with an 82% year-over-year revenue surge to $83.3 million, driven by new drug launches Revuforj and Niktimvo. The breadth of beats across different market caps and therapeutic areas is the defining characteristic of this Q3 cycle, distinguishing it from periods where only a few names delivered positive surprises.

BioMarin's $1,025 million result is particularly notable as it reflects continued growth in its metabolic conditions portfolio, a relatively rare disease space where BioMarin has built a commanding market position over decades. Vertex's strong cystic fibrosis franchise performance alongside its Crinetics acquisition integration demonstrates that large-cap pharma can grow through both organic drug commercialization and strategic M&A. Jazz Pharmaceuticals beat revenue estimates despite charges tied to the Actio acquisition that weighed on GAAP and non-GAAP per-share metrics.

The CRISPR Therapeutics beat—$12.7 million revenue against a $10.49 million consensus estimate—is significant for the gene therapy sub-sector. While the loss per share of $1.15 versus a $0.98 expected represents a miss on the bottom line, the revenue beat confirms that the company's gene therapy products are gaining commercial traction ahead of schedule. For sector investors, the collective Q3 performance across six names supports continued confidence in US pharma's growth trajectory through the balance of 2026 and into 2027.

Synthesized from 6 sources.